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Dysregulation of TFH-B-TRM lymphocyte
cooperation is associated with unfavorable
anti-PD-1 responses in EGFR-mutant lung cancer
Jae-Won Cho1, Seyeon Park2, Gamin Kim3, Heonjong Han1, Hyo Sup Shim 4, Sunhye Shin3, Yong-Soo Bae 5,
Seong Yong Park 6✉, Sang-Jun Ha 2✉, Insuk Lee 1✉ & Hye Ryun Kim 3✉
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear
mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we
compare tumor-infiltrating lymphocytes between EGFR mutant (EGFR-MT) and wild type
(EGFR-WT) tumors through single-cell transcriptomic analysis. We find that B cells, CXCL13-
producing follicular helper CD4+ T (TFH)-like cells, and tissue-resident memory CD8+ T
(TRM)-like cells decreased in EGFR-MT tumors. The NOTCH-RBPJ regulatory network, which
is vital for persistence of TRM state, is perturbed, and the interactions between TFH and B cells
through the CXCL13-CXCR5 axis disappear in EGFR-MT tumors. Notably, the proportion of
TRM-like cells is predictive for anti-PD-1 response in NSCLC. Our findings suggest that the
impairment of TFH-B-TRM cooperation in tertiary lymphoid structure formation, accompanied
by the dysregulation of TRM homeostasis and the loss of TFH-B crosstalk, underlies unfa-
vorable anti-PD-1 response in EGFR-MT lung tumors.
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Epidermal growth factor receptor (EGFR) mutations aremajor drivers of oncogenic alterations that account for animportant molecular subtype of lung adenocarcinoma,
comprising 40–60% of cases in the South-East Asian population
and 10–20% among Caucasian patients1. Patients with lung
cancer with sensitizing-EGFR mutations clinically benefit from
EGFR-tyrosine kinase inhibitors (TKIs) as first-line therapies1–3.
However, acquired resistance inevitably develops within
9–18 months, which is the main limitation to the effectiveness of
EGFR-TKIs1–3.
Programmed death receptor-1 (PD-1) inhibitors improve
survival outcomes by offering a durable response in patients with
non-small cell lung cancer (NSCLC)4–7. Accordingly, these
inhibitors are used as first- and second-line therapies for
NSCLC4–7. With the increase in the number of checkpoint
inhibitor-based clinical trials being conducted, interest in inte-
grating immunotherapy for patients with EGFR-mutant type
(EGFR-MT) lung cancer has also increased. However, recent
large-scale clinical trials and meta-analysis data have revealed
unfavorable treatment outcomes of these EGFR-MT patients
compared to those with EGFR wild-type (EGFR-WT), indicating
that patients with EGFR-MT do not benefit from PD-1
inhibitors8–10. In addition, pembrolizumab for the treatment of
PD-L1-positive EGFR-TKI naive patients with sensitizing-EGFR
mutation did not show objective response benefit11. A recent
clinical trial study reported that a combination of an anti-PD-L1
inhibitor, atezolizumab, with bevacizumab and chemotherapy
showed a survival benefit in pretreated EGFR-MT patients who
had failed TKI12. Determining the mechanisms underlying the
lower efficacy of PD-1 inhibitors in patients with EGFR-MT than
EGFR-WT can guide the development of treatment strategies to
improve the survival outcomes of these patients.
We predicted that the TME of EGFR-MT tumors differs from
that of EGFR-WT tumors in patients with NSCLC. However,
previous studies using immunohistochemistry (IHC) approa-
ches did not comprehensively compare the TMEs of the two
lung cancer subtypes. Single-cell RNA sequencing (scRNA-seq)
enables high-resolution dissection of cellular heterogeneity of
solid tissues, including tumors. A systematic comparison of
single-cell transcriptome profiles between EGFR-WT and
EGFR-MT tumors can reveal immune cell subsets that differ-
entially accumulate between groups of molecular subtypes in
NSCLC tumors, some of which may provide important clues
regarding their difference in clinical outcomes. Additionally,
identifying biomarkers and therapeutic targets can improve
anti-PD-1 immunotherapy. Although multiple scRNA-seq
studies have depicted immune cell landscapes of lung
cancers13–16, EGFR-WT and EGFR-MT tumors have not been
systematically compared.
In this work, we compare the single-cell transcriptome of
tumor-infiltrating immune cells between the two molecular sub-
types of lung cancer and seek key cell subsets and their molecular
features associated with EGFR mutation. We find that B cells,
CXCL13-producing follicular helper CD4+ T (TFH)-like cells, and
tissue-resident memory CD8+ T (TRM)-like cells are depleted in
EGFR-MT compared to EGFR-WT. Homeostasis of TRM cells
and CXCL13–CXCR5 axis-mediated crosstalk between TFH and B
cells are dysregulated in EGFR-MT tumors. Finally, the propor-
tion of cytotoxic TRM-like cells estimated by the expression sig-
nature reveals a highly predictive value for the anti-PD-1
response. Altogether, these results suggest the importance of
TFH–B–TRM lymphocyte cooperation in the formation of tertiary
lymphoid structure (TLS) for antitumor immunity. Furthermore,
its impairment in EGFR-MT tumor results in an unfavorable
response to anti-PD-1 immunotherapy.
Results
Comparative scRNA-seq analysis reveals immune cell subsets
differentially accumulated between EGFR-mutant and wild-
type tumors in NSCLC. To compare the cellular landscape
between two different molecular subtypes of lung cancer based on
the EGFR mutation status, we prepared tumor specimens surgi-
cally resected from 10 patients with NSCLC in stages IA–IIIA:
five EGFR-WT and five EGFR-MT (Supplementary Data 1).
Focusing on the landscape of tumor-infiltrating immune cells, we
sorted CD45+ leukocytes from tumor tissues and conducted
scRNA-seq using 10X Genomics technology for individual
patients (Fig. 1a and Supplementary Fig. S1). A total of 33,719
cells were sequenced, 31,887 of which passed quality control
(Supplementary Data 1). We preprocessed scRNA-seq data using
Seurat v.3.0 package17 and visualized them through UMAP
dimension reduction18. Systematic bias was observed among data
sets across different patients (Fig. 1b). To correct batch effects,
scRNA-seq data were integrated using Seurat v.3.0, which is based
on canonical correlation analysis and anchoring data sets between
samples17. After batch correction, the homogeneous population
structures of patients and mutation status were reduced in the
latent space by UMAP dimensions (Fig. 1c). Using the Louvain
algorithm of network community detection, we defined 18 clus-
ters (C0–17) corresponding to distinct cell subpopulations
(Fig. 1d). Based on the expression of canonical marker genes
(Supplementary Fig. S2), we annotated clusters for major cell
types such as CD8+ T cell (C0, C2, C11, and C14) (Supple-
mentary Figs. S3 and 4), CD4+ T cell (C1, C3, C5, C6, and C9)
(Supplementary Figs. S3 and 4), regulatory T cell (C4) (Supple-
mentary Figs. S3 and 4), natural killer (NK) cell (C13) (Supple-
mentary Fig. S5), natural killer T (NKT) cell (C7, C10, and C12)
(Supplementary Fig. S5), B cell (C8) (Supplementary Fig. S6),
macrophage and monocyte (C15) (Supplementary Fig. S7), den-
dritic cell (DC) (C16) (Supplementary Fig. S8), and innate lym-
phoid cell 2 (ILC2) (C17) (Supplementary Fig. S9). Many clusters
apparently had unequal cell distributions between EGFR-WT and
EGFR-MT (Fig. 1e), indicating differences in the composition of
tumor-infiltrating immune cells between the two molecular sub-
types of NSCLC. The majority of the clusters were composed of
cells derived from most of the 10 patients without severe bias
toward a specific patient. However, the three smallest clusters—
C15 (macrophage and monocyte), C16 (DC), and C17 (ILC2)—
were mostly derived from patient 6 (P6) (Fig. 1f and Supple-
mentary Data 2). Thus, we excluded these clusters from down-
stream analyses to avoid formulating hypotheses based on
patient-biased data.
To investigate proportional changes across the 15 cell subsets
(C0–C14) between EFGR-WT and EGFR-MT, we evaluated
deviations in the observed cell count from the expected counts for
each subset using Pearson residual (r). As the sign of the residual
indicates the direction of the difference in the observed count
from the expected count, r > 0 and r < 0 represent augmentation
and depletion compared to the expected count, respectively. We
considered only subsets with r > 3.5 and r <−3.5 as augmentation
and depletion with high confidence, respectively, for follow-up
functional interpretation (see “Methods” section for a detailed
description of r threshold selection). We visualized the results of
the goodness of fit test using a mosaic plot, in which subsets with
a deviation of observed from expected cell counts are indicated in
blue (augmentation), red (depletion), or gray (no significant
change) (Fig. 1g). The goodness of fit for all subsets was also
evaluated by the chi-square statistic (p-value of Fig. 1g). We
observed above-threshold level augmentation or depletion (r > 3.5
or r <−3.5) of the cell count for EGFR-WT and EGFR-MT from
eight subsets (Supplementary Data 2). We expected that a
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successful interpretation of differentially accumulated subsets
between EGFR-WT and EGFR-MT would provide clues to
understanding the mechanisms underlying unfavorable anti-PD-
1 response in patients with EGFR-MT NSCLC. To characterize
individual subsets for each major cell type (e.g., CD8+ T, CD4+
T, Treg, NK, NKT, and B cells), we identified differentially
expressed genes (DEGs) of a subset compared to all other subsets
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Fig. 1 Overview of comparative scRNA-seq analysis for lung tumor samples. a Schematic overview of scRNA-seq analysis for lung tumor samples from
10 patients (P1–10) of mutant or wild-type EGFR. b, c UMAP visualization of scRNA-seq data before (b) and after (c) batch correction. d UMAP plot of 18
clusters (C0–17) of immune cells categorized into major immune cell types. The order of cluster number corresponds to the relative cell count. Clusters
were annotated by canonical marker gene expression. e UMAP plot of 18 clusters of immune cells from either EGFR-WT (left) or EGFR-MT (right).
f Stacked-barplot of the cell count for each patient in 18 clusters. g Mosaic plot of 18 clusters, each of which is composed of EGFR-WT and EGFR-MT
groups. Red color indicates significantly decrease in abundance, whereas blue color indicates significantly increase in abundance (|Pearson residual| > 2 for
p-value < 0.05, |Pearson residual| > 4 for p-value < 0.0001). The p-value shown in the mosaic plot was obtained from a one-sided chi-square test. Source
data are provided as a Source Data file.
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EGFR-WT and EGFR-MT for each subset (group-DEG)
(Supplementary Data 3).
Proportion of cytotoxic NK cells decreases, whereas that of
NKT cells with low cytotoxicity increases in EGFR-MT tumors.
NK and NKT cells are cytotoxic lymphocytes of the innate
immune system that provide the first line of defense in the body
before activating the adaptive immune system. Although these
cells have a limited range of antigen specificity and lower capacity
for memory-generation, they can kill cancer cells directly via
cytotoxic molecules19. The subset of cytotoxic NK cells (C13) was
depleted in EGFR-MT, although its significance was not above
the pre-determined threshold (r=−3.34) (Fig. 2a). Among the
three subsets for NKT cells (C7, C10, and C12), the proportion of
NKT-C7 and NKT-C10 was significantly augmented in EGFR-
MT (r= 6.35 and 10.57, respectively; Fig. 2a). The subset-DEG
analysis revealed that NK-C13 and NTK-C12, which were
depleted and unchanged in EGFR-MT, respectively, expressed
more genes involved in activation (TNFRSF18, IL2RB, CD7,
CD44, TYROBP, and TNFRSF1B)20–22 (Fig. 2b) and cytotoxicity
(PRF1 and GZMB)23 (Fig. 2c) than other subsets. In contrast,
NKT-C7 and NKT-C10 proportion increased in EGFR-MT and
these subsets expressed genes involved in either activation or
cytotoxicity at lower levels than in other subsets. Overall, NKT-
C10 is likely to have the lowest cytotoxic activity among all NK
and NKT cell subsets, as the expression of genes involved in
activation and cytotoxicity was lower than that in all other subsets
(Fig. 2b, c), which is consistent with the highest augmentation in
EGFR-MT (r= 10.57) (Fig. 2a). In summary, single-cell tran-
scriptome analysis revealed the augmentation of NKT cell subsets
with relatively low expression of genes involved in activation and
cytotoxicity in EGFR-MT.
Proportion of B cells decreases with reduced antigen pre-
sentation in EGFR-MT tumors. B cells secrete antibodies to
neutralize antigens or tag tumor cells for attack by other immune
cells24. Recently, tumor-infiltrated B cells have been reported to
promote the response to immunotherapy and survival in cancer
patients through the formation of TLSs, in which B cells can
present a tumor-derived neoantigen to T cells to activate
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Fig. 2 Characterization of subsets for NK, NKT, and B cells based on marker gene expression. a UMAP and mosaic plots for NK and NKT cells. The
p-value shown in the mosaic plot was obtained from a one-sided Chi-square test. b, c Violin plots for the expression of genes involved in activation (b) and
cytotoxicity (c) of NK or NKT lymphocytes across subsets (H, high expression level; L, low expression level). Each subset was characterized based on the
expression levels of genes involved in activation and cytotoxicity. For example, NKT-C7 was characterized by low activation and high cytotoxicity. d UMAP
and mosaic plots for B cells. e Violin plots for the expression of genes involved in antigen presentation and processing in B cells of EGFR-WT or EGFR-
MT tumor.
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EGFR-MT compared to EGFR-WT (r=−6.23, Fig. 2d), sug-
gesting that EGFR-MT tumor has a lower proportion of tumor-
infiltrating B cells than EGFR-WT. In addition, we observed that
B cells from EGFR-MT showed lower expression levels of HLA
genes (MHC class I: HLA-C and MHC class II: HLA-DPB1, HLA-
DRB5, and HLA-DQA2) and TAP1 (antigen peptide transporter
involved in processing antigens that will be presented to MHC
class I) (Fig. 2e). These results suggest that B cells in EGFR-MT
tend to less effectively activate both CD8+ and CD4+ T cells than
EGFR-WT, due to the lower expression of MHC class I and II,
respectively.
Proportion of CXCL13-producing TFH-like cells decreases,
whereas that of immunosuppressive CD4+ T cells increases in
EGFR-MT tumors. Along with CD8+ T cells, CD4+ T cells are
major lymphocytes governing adaptive immunity; they differ-
entiate into diverse types of helper T cells that activate other
immune cells, including cytotoxic T cells. Accordingly, various
conventional CD4+ T cells are involved in antitumor or tumor-
promoting processes, whereas CD4+ Treg suppresses antitumor
immunity in the TME. We obtained six subsets of CD4+ T cells
(Fig. 3a), which were characterized by subset-DEG analysis for
various categories of immune signature genes (Fig. 3b). Among
the six CD4+ subsets, the two largest ones showed significant
augmentation in EGFR-MT (C1 and C3 by r= 8.48 and 7.66,
respectively). We found that these subsets showed a high
expression of genes involved in CD4+ T cell-mediated immune
suppression (CD5229,30, ANXA131,32, ANXA233, and CXCR434).
The C5 subset, for which the marker-based cellular identity was
relatively unclear, showed augmentation in EGFR-MT with a
subthreshold level of significance (r= 2.74). The C6 subset,
annotated as naive CD4+ T cells based on the high expression of
CCR7 and SELL, showed no significant difference in relative
abundance between EGFR-WT and EGFR-MT.
Notably, the C9 subset was CD4+ T cells with the largest
depletion in EGFR-MT (r=−7.37). We found several genes
related to TFH cells (CXCL1335, ICOS36, MAF37, PDCD135, and
SH2D1A35) among the subset-DEGs for C9 (Fig. 3b, c and
Supplementary Data 3). TFH cells reportedly help B cells by
promoting the maturation of antibody affinity in germinal centers
(GC)35. PD-1 regulates GC positioning and helps with the
function of TFH cells38. Human TFH cells produce CXCL13, a
major chemoattractant in homing B cells to follicles35. CXCL13
has been associated with TLS development39,40. CXCR5, a
receptor for CXCL13 and another hallmark of TFH cells, was
not detected as a subset-DEG of C9. Moreover, the C9 subset does
not express BCL6, a lineage-defining transcription factor of TFH
cells35. These CXCR5 and BCL6-negative TFH-like cells that
produce CXCL13 are found in local inflammatory sites41, where
TLS development frequently occurs42. Given that the major role
of the TFH cells is to recruit B cells, depletion of CXCL13-
producing TFH-like cells in EGFR-MT may result in the
inefficient formation of TLS. The observed depletion of tumor-
infiltrating B cells (Fig. 2d) also suggests lower TLS development
in EGFR-MT. Recently, B cells and TLS have been shown to be
associated with responses to immunotherapy26–28. We also
observed a substantially lower level of CXCL13 expression in
EGFR-MT than in EGFR-WT tumor (Fig. 3d), which further
supports the hypothesis that CXCL13-producing TFH-like cells
contribute to the anti-PD-1 response through recruiting B cells to
functional TLS in tumors. To confirm the reduced abundance of
CXCL13+CD4+ T cells in EGFR-MT compared with EGFR-WT
tumor, inferred from the single-cell transcriptome analysis, we
performed the multiplexed immunofluorescence (IF) staining in
archival tissue specimens of the same samples. We could obtain
results of multiplexed IF for nine of the prior samples, because the
sample quantity for the P3 patient was not sufficient for the
downstream analysis. The results of multiplexed IF confirmed
the reduced number of CD4+ and CXCL13+CD4+ T cells in
EGFR-MT compared with EGFR-WT tumors (Fig. 3e, f and
Supplementary Figs. S10, S11, Supplementary Data 4a). Although
not statistically significant due to the small sample size, these
results are congruous with the observations from the single-cell
transcriptional analysis. To validate these findings further, we
performed a similar analysis on a validation set of tumor samples
from 19 independent NSCLC patients with EGFR-WT (n= 9) or
EGFR-MT (n= 10) (Supplementary Data 5a). For this validation
set with a larger sample size, we could observe significantly
reduced frequencies of CXCL13+CD4+ T cells in EGFR-MT
compared with EGFR-WT tumors for the validation set (Fig. 3g
and Supplementary Fig. S12, Supplementary Data 4c).
The C4 subset was annotated as Treg cells based on the high
expression signature genes of tumor-infiltrating Tregs (FOXP3,
IL2RA, IL2RB, IL2RG, IL10RA, MAGEH1, LAYN, and GATA3).
They also showed a high expression of genes involved in T cell
activation (CD27, CD28, ICOS, and TNFRSF4 encoding OX40,
TNFRSF9 encoding 41BB, and TNFRSF18 encoding GITR) and
checkpoint molecules (TIGIT and CTLA4). Counterintuitively,
we observed a depletion of the Treg subset in EGFR-MT
(Fig. 3a). However, we also found that Treg cells of EGFR-MT
tumors expressed genes known to promote Treg activity
(TSC22D3 encoding GILZ43 and NR4A244) at levels significantly
higher than those in EGFR-WT (Fig. 3h and Supplementary
Data 3), which may compensate for its disadvantages in
abundance.
Proportion of cytotoxic CD8+ TRM-like cells decreases in
EGFR-MT tumors. CD8+ T cells were clustered into four dif-
ferent subsets (C0, C2, C11, and C14), among which, only C2
exhibited significant differences in its proportion between EGFR-
WT and EGFR-MT, particularly depletion in EGFR-MT
(r=−6.44) (Fig. 4a). We characterized each subset of CD8+
T cells based on the expression of various categories of signature
genes (Fig. 4b) and found that the C2 subset had the highest
cytotoxicity and expressed ITGAE (also known as CD103), a
hallmark of TRM cells45. In addition, the C2 subset showed a
significantly higher effector signature (ID2 and IFNG) and
memory signature (CD7). TRM cells are a subset of effector
memory T cells in the peripheral tissue, and their roles in anti-
tumor immunity have recently gained considerable attention46,47.
We also found that the C2 subset highly expressed the signature
genes for tumor-infiltrating TRM-like CD8+ T cells such as
PDCD1, HAVCR2, and LAG3, but rarely expressed TCF7, a lung
TRM suppressor48–50 (Fig. 4b). Previously, HAVCR2 (also known
as TIM-3) expression has been reported as a feature of lung tumor
TRM cells that are not involved in exhaustion but rather reflect a
functional state49. In this regard, we defined the C2 subset as
TRM-like cells. As a fast-reactive memory T cell subset, TRM cells
constitutively express perforin (PRF1), granzyme B (GZMB), and
IFN-gamma (IFNG). We found that the tumor-infiltrating TRM-
like subset expressed a high level of GZMB, whereas other subsets
showed much lower expression, indicating the TRM-like subset as
a major cytolytic lymphocyte in the tumor (Fig. 4c). High
expression of ENTPD1 (also known as CD39) indicates that the
C2 subset is composed of tumor-reactive TRM-like cells rather
than bystander T cells51 (Fig. 4d). The expression of effector
molecules and markers for naive/memory states suggest that C0
and C11 are effector CD8+ T cell subsets with lower cytotoxicity,
and C14 is a naive T cell subset (Fig. 4e, f). Notably, we observed
a higher expression of GZMB and genes involved in T cell
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activation in TRM-like cells from EGFR-WT than in those from
EGFR-MT (Fig. 4g), indicating that TRM-like cells in EGFR-WT
tumors have the highest antitumor activity for the direct killing of
cancer cells.
We evaluated the protein expression of selected molecules
(CD8, CD103, and GZMB) using multiplexed IF for the whole
slides to confirm the presence of TRM-like cells in an archival
tissue specimen. The abundance of CD8+, CD103+CD8+, and
GZMB+ CD103+CD8+ T cells tended to be lower in EGFR-MT
than EGFR-WT (Fig. 4h, i and Supplementary Figs. S10, 11,
Supplementary Data 4a), consistent with the results based on the
transcriptional level. For the validation set of tumor samples from
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19 independent NSCLC patients (Supplementary Data 5a), we
could observe a significantly lower abundance of CD8+ and
CD103+CD8+ T cells in EGFR-MT compared with EGFR-WT
(Fig. 4j and Supplementary Fig. S12, Supplementary Data 4c). For
further validation, we performed a flow cytometry analysis using
multiple antibodies, including anti-CD8, anti-CD103, and anti-
GZMB for another validation set that consist of tumors from
independent 35 NSCLC patients with EGFR-WT (n= 16) or
EGFR-MT (n= 19) (Supplementary Data 5b). The TRM-like cell
subset was highly enriched for cells with a high expression of both
CD103 and GZMB (area within the solid circle) among CD8+
cells (area within the dotted circle) in EGFR-WT compared to
EGFR-MT (Fig. 4k). The proportion of CD103+ cells among
CD8+ cells and that of GZMB+ cells among CD8+CD103+ cells
was significantly lower in EGFR-MT than EGFR-WT (Fig. 4l, m).
Therefore, the depletion of CD8+ TRM-like cells in EGFR-MT
lung tumors was confirmed by protein-based immunophenotyp-
ing analysis.
Homeostasis of TRM-like cells is impaired in EGFR-MT
tumors. Hitherto our comparative single-cell transcriptome
analysis between EGFR-WT and EGFR-MT revealed three lym-
phocyte subsets significantly depleted in lung tumors with EGFR
mutations: B cells, CD4+ TFH-like cells, and CD8+ TRM-like cells.
Given that patients with lung cancer with EGFR mutations
exhibit unfavorable anti-PD-1 responses, regulation of coopera-
tion among these lymphocyte subsets may be important for
antitumor immunity in lung tumors. Based on the constitutively
high expression of major cytolytic enzymes, such as perforin and
GZMB, in TRM-like cells, the persistence of TRM cell state in a
tumor may be a major determinant of the effective killing of
cancer cells.
To evaluate the homeostasis of TRM-like cells in EGFR-WT and
EGFR-MT tumors, we measured the transition probability
between CD8+ subsets (C0, C2, C11, and C14; Fig. 5a) based
on RNA velocity analysis using velocyto52, which can be
estimated from the ratio of unspliced to spliced mRNA. Based
on the probability of future mRNA abundance for all genes, we
can predict the future state (subset) of each cell (Fig. 5b). For
example, the mean transition probability from C2 to C0 was
higher in EGFR-MT than in EGFR-WT, whereas that from C2 to
C2 (that is, the persistence of C2 state) was higher in EGFR-WT
than in EGFR-MT (Fig. 5c). We compared and calculated the
transition probability among four subsets, C0, C2, C11, and C14,
between EGFR-WT and EGFR-MT tumors to identify the
changes in homeostasis. Notably, C2 (TRM-like cells) derived
from EGFR-WT and EGFR-MT showed probabilities of 0.57 and
0.41 for persistence, respectively (Fig. 5d and Supplementary
Data 6). In contrast, all other subsets showed similar probabilities
for persistence between EGFR-WT and EGFR-MT: 0.77 vs. 0.76
for C0, 0.16 vs. 0.16 for C11, and 0.042 vs. 0.034 for C14. We also
performed scVelo53 analysis that enables estimation of RNA
velocity without steady-state assumption and observed consistent
results (Supplementary Fig. S13). These results suggest that the
persistence of the TRM cell state is impaired in EGFR-MT lung
tumors.
NOTCH-RBPJ regulatory network for maintaining TRM cells is
perturbed in EGFR-MT tumors. Transcriptional regulatory
networks tightly control differentiation and functional main-
tenance of immune cells. We hypothesized that the dysregulation
of the transcriptional regulatory network for homeostasis in the
TRM cell state occurs in EGFR-MT lung tumors. To reconstruct
the key regulatory network, we first identified differentially
upregulated transcription factors (TFs) in the C2 subset com-
pared to other CD8+ cell subsets (Fig. 5e). Among the upregu-
lated TFs, ID2, RBPJ, and BHLHE40 are known to be involved in
TRM cell development and homeostasis54–56. Particularly, RBPJ is
associated with NOTCH to form a transcriptional activator
required for maintaining TRM cells in humans55. Next, we com-
pared the co-regulatory network of RBPJ between EGFR-WT and
EGFR-MT to identify the gain or loss of regulatory targets for
RBPJ between the two molecular subtypes of lung tumors. To
improve the robustness of gene-gene correlation analysis for
highly sparse scRNA-seq data, we employed the MetaCell57
analysis method, which partitions single-cell transcriptome pro-
files into disjoint and homogeneous groups of profiles. As
expected, we observed a high correlation of expression between
RBPJ and many known genes for TRM cell differentiation and
maintenance45–47 in C2 subset cells from EGFR-WT tumors
(Fig. 5f). Additionally, NOTCH1 showed a high correlation with
the same regulatory target genes, although it was not significantly
upregulated in the C2 subset compared with other CD8+ cell
subsets. Interestingly, many transcriptional correlations with
RBPJ disappeared in the C2 subset cells of EGFR-MT. Particu-
larly, the expression of RGS2, NOTCH1, RGS1, PDCD1, CRTAM,
CXCR6, TIA1, HIF1A, NAB1, and ITGAE positively correlated
with RBPJ in the C2 subset of EGFR-WT, but the gene-gene
correlations were lost or even inversely correlated in the C2 subset
of EGFR-MT (Fig. 5g and Supplementary Data 7). The loss of the
transcriptional correlation in EGFR-MT was more marked with
NOTCH1 (Fig. 5f and Supplementary Data 7). These results
indicate that the persistence of the tumor-infiltrating TRM cell
state depends on the NOTCH-RBPJ regulatory network, which is
dysregulated in EGFR-MT lung tumors.
Proportion of tumor-infiltrating TRM-like cells is highly pre-
dictive for anti-PD-1 response in NSCLC. Given that the pro-
portion of tumor-infiltrating TRM-like cells decrease in EGFR-MT
lung tumors, which tends to show poor response to anti-PD-1
immunotherapy, we hypothesized that the relative abundance of
TRM-like cells in the tumor by itself could predict the anti-PD-1
response. The current gold-standard estimation of the proportion
of each immune cell type is flow cytometry analysis using cano-
nical markers specific for each cell type. However, this approach
is valid for only major cell types or subtypes with well-
Fig. 3 Characterization of subsets for CD4+ T cells based on marker gene expression and multiplexed immunofluorescence (IF) analysis. a UMAP and
mosaic plot for CD4+ T cells. The p-value shown in the mosaic plot was obtained from a one-sided chi-square test. b Dot plots for the expression of marker
genes for various functional properties of CD4+ T cells. Subset-DEGs are represented as a red circle with statistical significance indicated by the dot
size. c Violin plots for the expression of genes related to follicular helper T cells across subsets. d Violin plots for the expression of CXCL13 genes in C9 cells
of EGFR-WT and EGFR-MT. e Representative multiplexed IF (scale bar 100 μm: left, scale bars 50 μm: right magnified) of CD4 and CXCL13 in tumor
specimens from EGFR-WT (n = 14) and EGFR-MT (n = 14) patients. Asterisks mark the double-positive CD4+CXCL13+ cells. f The cell counts of CD4+,
CXCL13+CD4+ T cells per mm2 of EGFR-WT (n = 5) and EGFR-MT (n = 4) tumors were depicted in the bar graph. g The cell counts of CD4+,
CXCL13+CD4+ T cells per mm2 of tumors from independent patients with EGFR-WT (n = 9) and EGFR-MT (n = 10) for validation were depicted in the bar
graph (*p≤ 0.05, two-sided test). h Violin plots for the expression of TSC22D3 and NR4A2, which are the genes involved in Treg activation, in C4 cells of
EGFR-WT and EGFR-MT. Data are represented as mean ± SEM. Source data are provided as a Source Data file.
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characterized marker genes. Single-cell biology enables discover-
ing an increasing number of cell subsets, and identifying specific
markers for the subsets would be a daunting task. Therefore,
quantifying cell subsets from a heterogeneous cell population
using cell-type-specific expression signature has recently been
employed. To infer the expression signature of the 18 subsets of
immune cells from lung tumor samples, we applied
CIBERSORTx58, a deconvolution method developed for inferring
gene expression signature for a specific cell type, to the single-cell
transcriptome profiles and generated a signature matrix of
18 subsets (Supplementary Data 8a). We then estimated the
relative abundance of TRM-like cells in The Cancer Genome Atlas
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(TCGA) cohort of lung adenocarcinoma (LUAD) and lung
squamous cell carcinoma (LUSC)59. Consistent with the single-
cell transcriptome results, the signature score for TRM-like cells
was significantly higher in TCGA tumors with wild-type EGFR
than in the mutant type (p= 0.0173, one-tailed Mann–Whitney
U test) (Fig. 5h and Supplementary Data 8b). This result confirms
that the inferred expression signature is a suitable estimator of the
relative abundance of TRM-like cells in the tumor.
Next, we evaluated the expression signature of TRM-like cells to
predict the response to anti-PD-1 immunotherapy using bulk
RNA-seq data and clinical information available for two
independent public cohorts of patients with NSCLC
(GSE126045 and GSE135222)60,61. Notably, we observed a
positive correlation between the signature score, indicating an
abundance of tumor-infiltrating TRM-like cells and anti-PD-1
response in both cohorts (Fig. 5i and Supplementary Data 8c, d).
In the two NSCLC cohorts, the signature score of responders was
significantly higher than that of non-responders (p= 0.0114 and
0.0404, one-tailed Mann–Whitney U test). Furthermore, we
prioritized patients exhibiting the highest signature score. This
stratification resulted in a large area under the receiver operating
characteristic curve (AUROC) scores, indicating that a high
abundance of tumor-infiltrating TRM-like cells is a predictive
marker of the anti-PD-1 response (Fig. 5j). Notably, only 2 of the
18 patients in the cohort recruited by Yonsei Cancer Center
(YCC)60 were EGFR-MT; one was a responder, whereas the other
was not (EGFR mutation status information was not available for
the cohort by Jung et al.61). Therefore, the identified expression
signature for TRM-like cells by itself can be used as a biomarker to
stratify patients with lung cancer for anti-PD-1 immunotherapy
regardless of their EGFR mutation status.
CXCL13–CXCR5-mediated TFH–B and TRM–B interactions are
dysregulated in EGFR-MT tumors. Previous studies also
demonstrated that TFH cells release CXCL13 to recruit B cells into
TLS35, which then present tumor antigens to T cells62. As
demonstrated in our study, the abundance of CXCL13-producing
TFH-like cells was higher in EGFR-WT than in EGFR-MT
patients (Fig. 3e, f). These observations suggest that recruiting B
cells into the TLS of the tumor become less effective in EGFR-
MT, likely due to a loss of CXCL13–CXCR5-mediated interac-
tions, resulting in reduced cytotoxic T cell activation. To test this
hypothesis, we evaluated cell-to-cell interactions among TFH-like
cells (C9), B cells (C8), and cytotoxic TRM-like cells (C2) using
CellPhoneDB63. We found more significant cell–cell interactions
in EGFR-WT than EGFR-MT (Fig. 6a). We found that TFH–B cell
interaction through the CXCL13–CXCR5 axis was substantially
weaker in EGFR-MT (lower mean expression of ligand and
receptor) than in EGFR-WT. Notably, we could also detect
CXCL13–CXCR5-mediated interactions between TRM–B cells in
EGFR-WT but not in EGFR-MT. Indeed, TRM-like cells also
express CXCL13, albeit not as much as in TFH-like cells.
Recently, a PD-1+CD8+ T cell subset that secretes CXCL13
has been detected close to the B cell area of the TLS in lung
cancer64. B cells of EGFR-WT appeared to present more
molecules involved in antigen processing and presentation than
EGFR-MT (Fig. 3d). These molecules will promote the activation
of CD4+ TFH-like cells (through MHC class II) and CD8+ TRM
cells (through MHC class I). Subsequently, the enhanced antigen-
presenting ability might boost B cell expansion and stimulate
tumor-specific CD8+ TRM cells. In EGFR-WT, the abundance of
CD8+ TRM-like cells and their GZMB production were higher
than those in EGFR-MT (Fig. 4h, i, k, m). Consequently, the
increased proportion of CD8+ TRM-like cells can effectively lyse
cancer cells by producing cytolytic materials such as GZMB.
To test our hypothesis, we first defined the area of TLS-like
lesion (see “Methods” section) and then evaluated the abundance
of TFH-like (CXCL13+CD4+), B (CXCR5+CD20+), and TRM-like
(CD103+CD8+) cells within the TLS-like lesions of archival
tumor tissue samples using multiplexed IF. Interestingly, we
found that the total area of TLS-like lesion was significantly
smaller in EGFR-MT than EGFR-WT (Fig. 6b, left and right
upper panels and Supplementary Data 4a). For the validation set
of 19 independent tumor samples used for multiplexed IF, we also
observed a smaller area of TLS-like lesion in EGFR-MT than
EGFR-WT (Fig. 6b, right lower panel and Supplementary
Data 4c). In overall TLS-like lesion, the much less number of
CD4+ and CD8+ T cells were found in EGFR-MT than EGFR-
WT (Fig. 6c, d and Supplementary Figs. S10, 11). Notably, the
numbers of TFH-like (CXCL13+CD4+) and TRM-like
(CD103+CD8+) cells in EGFR-MT were significantly lower than
EGFR-WT (Fig. 6c, d and Supplementary Figs. S10, 11,
Supplementary Data 4b). We observed consistent results from
the validation set of 19 independent tumor samples (Fig. 6e and
Supplementary Fig. S12, Supplementary Data 4d). These results
altogether suggest that CXCL13–CXCR5-mediated interactions
between TFH–B and TRM–B cells scaffold TFH–B–TRM lympho-
cyte cooperation in TLS for antitumor immunity in lung cancer
as summarized in Fig. 6f.
Fig. 4 Characterization of subsets for CD8+ T cells based on marker gene expression, multiplexed immunofluorescence (IF), and flow cytometry
analysis. a UMAP and mosaic plot for CD8+ T cells. The p-value shown in the mosaic plot was obtained from a one-sided chi-square test. b Dot plots for
the expression of marker genes affecting various functional properties of CD8+ T cells. Subset-DEGs are indicated as red circles, with statistical
significance indicated by the size of the dot. c Violin plots for the expression of genes involved in cytotoxicity. d Violin plots for the expression of hallmark
genes for tissue-residency (ITGAE) and tumor reactivity (ENTPD1) of CD8+ T cell subset. The expression levels for individual cells are indicated along with
the violin plot, and the proportion (%) of cells that express each hallmark gene is also presented. e Violin plots for the expression of genes related to
effector function. f Violin plots for the expression of genes related to the naive or memory state of T cells. g Violin plots for the expression of genes
involved in cytotoxicity and T cell activation. Violin plots for two groups (EGFR-WT and EGFR-MT) are fused to facilitate comparison. DEGs with a higher
expression for EGFR-WT are indicated as group-DEG. h Representative multiplexed IF of CD8, CD103, and GZMB in tumor specimens from EGFR-WT (n =
14) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT (n = 14) (scale bar 100 μm: left, scale bars 50 μm: right magnified) patients.
Asterisks mark the triple-positive CD8+CD103+GZMB+ cells. i The cell counts of CD8+, CD8+CD103+, and CD8+CD103+GZMB+ per mm2 in EGFR-WT
(n = 5) and EGFR-MT (n = 4) patients are depicted in the bar graph. j The cell counts of CD8+ and CD8+CD103+ per mm2 tumors collected from
independent patients with EGFR-WT (n = 9) and EGFR-MT (n = 10) for validation were presented in the bar graph (*p≤ 0.05, two-sided test). k tSNE
visualization of flow cytometry data from 7000 randomly selected live and singlet-gated CD3+ cells isolated from EGFR-WT (n = 3) and EGFR-MT (n = 3)
tumor samples. Each cell is marked by a dot whose color scales according to the z-score expression value of the indicated protein (CD8, CD103, or GZMB).
l Representative contour plot and summarized graph for the expression of CD103+ cells among the CD8+ T cells in EGFR-WT (n = 16) and EGFR-MT (n =
19) tumors collected from independent patients for validation (*p≤ 0.05, two-sided test). m Representative histogram and summarized graph for the
expression of GZMB+ cells among CD8+CD103+ T cells in EGFR-WT (n = 16) and EGFR-MT (n = 19) tumors collected from independent patients for
validation (*p≤ 0.05, two-sided test). Data are represented as mean ± SEM. Source data are provided as a Source Data file.
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Discussion
In the present study, we performed comparative single-cell
transcriptome analysis between EGFR-WT and EGFR-MT lung
tumors across subsets of CD45+ immune cells using scRNA-seq
to elucidate the underlying mechanisms of the different response
rates to anti-PD-1 immunotherapy. Recently, accumulating
evidence has indicated that activating the oncogenic pathway in
tumor cells could diminish the antitumor immune response by
modulating immune cell differentiation and recruitment65. Our
study reveals the significant depletion of tumor-infiltrating B
cells, CD4+ TFH-like cells, and CD8+ TRM-like cells in EGFR-MT
tumors. In addition, TFH-like, B, and TRM-like cells of EGFR-MT
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showed a lower expression of genes involved in TLS formation,
antigen presentation, and cytotoxicity, respectively, than EGFR-
WT. EGFR-WT and EGFR-MT patient groups showed bias
towards males with smoking history and female non-smokers,
respectively, in both discovery and validation cohorts. Previous
studies also reported a higher prevalence of EGFR-mutant
NSCLC in female non-smokers than male smokers66,67. To test
whether gender or smoking status was a confounder of the
observed depletion of TFH-like, B, and TRM-like cells in EGFR-
MT tumors, we compared CIBERSORTx scores for the three cell
types between different smoking status or genders in EGFR-WT
and EGFR-MT groups of the NSCLC tumors of TCGA cohort,
separately. In neither EGFR-WT nor EGFR-MT group, we could
observe a significant decrease of the three cell types in non-
smokers and females (Supplementary Fig. S14a), which indicates
that neither smoking status nor gender was a confounder of the
observed association between EGFR mutation status and TME
phenotypes. In addition, we observed only a weak correlation of
TRM-like cell abundance or TLS area with PD-L1 expression
(Supplementary Fig. S14b), which suggests that PD-L1 was not a
confounder of our observed association between EGFR mutation
status and TME phenotypes. Altogether, these results suggest that
a higher intrinsic resistance of EGFR-mutant tumors to anti-PD-1
immunotherapy is primarily due to the depletion of these three
lymphocyte subsets, major functional components of TLS for
antitumor immunity, and their dysfunctional modulation in
tumors. Furthermore, we found the disappearance of TFH–B and
TRM–B interactions mediated by the CXCL13–CXCR5 axis in
EGFR-MT tumors, which may negatively affect the formation of
TLS in the tumor. Thus, targeting genes involved in these intra-
and inter-cellular networks may improve the anti-PD-1 response
in EGFR-MT patients.
Previous studies have demonstrated a correlation between the
intratumoral abundance of TRM cells and patient prognosis in
lung cancer49,68,69. In this study, we demonstrate the feasibility of
predicting the response to anti-PD-1 immunotherapy based on
the proportion of TRM-like cells. Quantification of a specific
intratumoral cell subset would be a useful biomarker for pre-
dicting clinical outcomes. Using the recently developed CIBER-
SORTx for gene expression deconvolution with single-cell
transcriptome data, we extracted expression signatures for each
cell subset in the lung tumor and found that CD8+ TRM-like cells
were highly predictive of the anti-PD-1 response in two inde-
pendent cohorts of NSCLC. Notably, we tested the expression
signature of TRM-like cells constructed from lung tumors to
identify anti-PD-1 responders in melanoma cohorts but observed
no prediction power. Given that TRM cells permanently reside in
the peripheral tissue, these results are attributable to the tissue-
specific nature of TRM cells by adaptation to different local
microenvironment.
In the present study, we employed Pearson residual analysis
with mosaic plot visualization to systematically compare the cell
subset distribution between sample groups (EGFR-WT and
EGFR-MT tumors). Using the chi-square significance test with
Bonferroni adjustment for multiple hypothesis tests, we could
retrieve subsets showing proportional changes that were con-
sistent with the observed phenotype differences between sample
groups. The same analytical framework can be applied to various
comparative single-cell transcriptome analyses between sample
groups with distinct genotypes and phenotypes, and the inter-
pretation of results is highly intuitive. The Pearson residual
method can be applied in a comparative analysis between more
than two groups, if not too many. Therefore, we anticipate
expanded the applicability of the Pearson residual framework to
single-cell transcriptome analysis in the future.
There are several limitations to this study. First, although we
identified three cell subsets associated with antitumor immunity
in the TLS area and their functional regulation, whether they are
regulated independently or hierarchically coordinated remains
unknown. For example, if CXCL13 produced by TFH-like cells
promotes the persistence of TRM-like cells by interacting with
recruited B cells, the transcriptional regulator of CXCL13
expression in T cells could be the primary target to improve an
anti-PD-1 response in EGFR-MT tumors. Second, this study lacks
data for myeloid cells (e.g., dendritic cells and myeloid-derived
suppressor cells) and stromal cells (e.g., cancer-associated fibro-
blasts), which also contribute to cancer–immune interactions.
Although they are not directly involved in killing cancer cells,
their activity enhances or suppresses major cytotoxic lymphocytes
through cytokine-mediated cell-to-cell communication and the
presentation of tumor antigens. Therefore, a comparison of
subsets of myeloid and stromal cells would reveal additional
cellular components for determining the response to anti-PD-1
immunotherapy. Third, our study cohort has a bias toward the
adenocarcinoma subtype of NSCLC (it includes only a single
patient with the squamous carcinoma subtype). Thus, some
findings from the present study are possibly relevant to the
adenocarcinoma subtype only. Fourth, two patients with G719A
(P5) and G719S (P8) were included in the present study.
Although G179X are considered sensitizing mutations, these were
not included in a phase 3 trial comparing osimertinib with other
EGFR-TKIs for EGFR-mutant NSCLC patients as first line
(FLAURA)3 and are under-represented in clinical trials compared
to exon 19del and L858R. Fifth, although we demonstrated that
Fig. 5 Regulation of TRM-like subset homeostasis that can predict anti-PD-1 responses in lung cancer. a UMAP plot for CD8+ T cells with color codes
for four distinct cell subsets. b Transition probability of cells is visualized on the predefined UMAP plots for CD8+ T cells of EGFR-WT and EGFR-MT tumors.
Only three major subsets of CD8+ T cells (C0, C2, and C11) are presented here. A longer arrow indicates a higher transition probability. c Histograms for the
distribution of transition probabilities from C2 subset to C0 subset (upper) and those from C2 subset to C2 subset (i.e., C2 persistence) in two different
tumor groups. From these histograms, C2 cells of EGFR-MT are more likely to transit to C0, whereas those of EGFR-WT tend to persist in the C2 state.
d Summary of transitions among the three major subsets. C0 and C11 showed no difference in persistence between EGFR-WT and EGFR-MT (middle and
bottom), whereas C2 showed higher persistence in EGFR-WT than in EGFR-MT (top). e Volcano plot showing DEGs in TRM-like cells (C2) compared
to other subsets of CD8+ T cells. TFs are indicated by red color. f Heat map visualization of Spearman’s rank correlation of RBPJ or NOTCH1 with genes
related to TRM cell differentiation or maintenance (columns) in EGFR-WT and EGFR-MT tumors. g Scatter plots with regression curves that highlight largely
decreased or even inversed correlation between RBPJ and potential regulatory target genes in EGFR-MT compared with EGFR-WT tumor. h Boxplot for the
abundance of TRM-like cells in EGFR-WT and EGFR-MT of TCGA LUAD and LUSC samples estimated by CIBERSORTx signature matrix score. i Waterfall
plot to depict anti-PD-1 response based on the cohorts of patients with NSCLC recruited from Yonsei Cancer Center (YCC) and patients with NSCLC from
Jung et al. The baseline represents the median level of CIBERSORTx score representing the proportion of the tumor-infiltrating TRM-like cells. All p-values
were calculated using the one-tailed Mann–Whitney U test (testing the association of responder status with the proportion of tumor-infiltrating TRM-like
cells). j Area under the receiver operating characteristics curve for retrieving responders based on the proportion of tumor-infiltrating TRM-like cells. Source
data are provided as a Source Data file.
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smoking status and genders are not confounders of the observed
decrease of TLS in EGFR mutants, we may not rule out other
confounding factors. Much large sample sets of genomically and
clinically annotated tumors will provide a more comprehensive
assessment of our findings. Finally, although we demonstrated
the importance of homeostasis of TRM-like cells for antitumor
immunity in TME of NSCLC through single-cell RNA
velocity and co-regulatory network analysis, we could not
provide functional validations in the present study. Thus, we
need to conduct further experimental analyses in vitro and
in vivo conditions to confirm our proposed mechanisms in
future study.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26362-0
12 NATURE COMMUNICATIONS |         (2021) 12:6068 | https://doi.org/10.1038/s41467-021-26362-0 | www.nature.com/naturecommunications
In conclusion, we performed a comparative single-cell tran-
scriptome analysis between EGFR-mutant and wild-type lung
tumors and found several key lymphocyte subsets involved in the
mechanisms underlying the anti-PD-1 response. In particular, we
elucidated that TFH–B–TRM lymphocyte cooperation is critical to
antitumor immunity in lung cancer. Dysregulation of the
homeostasis of TRM cell state and TFH–B and TRM–B crosstalk
involved in TLS development in EGFR-MT lung tumor may
account for unfavorable responses to the antitumor immu-
notherapy with PD-1 blockades. Our findings provide guidelines
for developing strategies to enhance anti-PD-1 efficacy in patients
with EGFR mutations.
Methods
Tumor specimen collection and preparation. Patients diagnosed with NSCLC
and who underwent surgical resection at Severance Hospital (Seoul, Republic of
Korea), between June 2018 and August 2018, were prospectively enrolled. We
consecutively enrolled five patients with EGFR-MT and five patients with EGFR-
WT lung cancer. As depicted in Supplementary Data 1, six patients were in
pathological stage I, two in stage II, and two in stage III; all patients with EGFR-MT
were female never smokers, and those with EGFR-WT were males with a smoking
history. This bias regarding the contribution of gender and smoking history to
EGFR mutation has been previously reported in Asian patients with lung
cancer66,67. No patient had undergone chemotherapy or radiation therapy before
surgical resection. The study was approved by the Institutional Review Board of
Severance Hospital (IRB No. 4-2018-1210, 4-2014-0775, and 4-2020-0945). We
have obtained written informed consents from all patients in this study.
We collected fresh tumor tissues on the day of the surgery, which were
mechanically and enzymatically dissociated using a gentleMACS dissociator
(Miltenyi Biotec, Gladbach Bergisch, Germany, Cat# 130-093-235) and the Human
Tumor Dissociation Kit (Miltenyi Biotec, Cat# 130-095-929) following the
manufacturer’s instructions. After incubation for 1 h at 37 °C, the resuspended
samples were filtered through a 70-µm-MACS SmartStrainer (Miltenyi Biotec, Cat#
130-098-462) into RPMI-1640 medium (Corning, Inc., Corning, NY, USA)
supplemented with 10% fetal bovine serum (Biowest, Riverside, MO, USA) and
centrifuged at 300 × g for 10 min. The pellet was suspended in PBS containing 2%
fetal bovine serum. For fluorescence-activated cell sorting (FACS) analysis, single-
cell suspensions were stained for 20 min at 4 °C with the following fluorescent-dye-
conjugated antibodies: LIVE/DEAD™ Fixable Red Dead Cell Stain Kit (Invitrogen,
Carlsbad, CA, USA, Cat# L23102. 1:100) and CD45 (Biolegend, San Diego, CA,
USA, clone 2D1. 1:100). The samples were sorted using a FACS Aria III sorter (BD
Biosciences, Franklin Lakes, NJ, USA) into live and single CD45+ cells. The sorted
cell population was analyzed to ensure successful cell sorting, as shown in
Supplementary Fig. S1. Cell viability was assessed by the Luna FL Fluorescence Cell
Counter (Logos Biosystems, Anyang, Korea, Cat#L20001) and confirmed to be
75–98% in all samples.
10× single-cell RNA sequencing. Single-cell samples for constructing libraries
and sequencing were prepared using a Chromium controller according to the 10×
Single Cell 3′ v2 protocol (10× Genomics, Pleasanton, CA, USA). To acquire 10,000
targeted cells, the cells were diluted in nuclease-free water and mixed with the
master mix. The single-cell suspensions were loaded with Single Cell 3′ Gel Beads
and Partitioning Oil (GEM) into a Single Cell 3′ Chip. To generate the GEMs,
single cells were uniquely barcoded, and cDNAs were used to construct libraries
according to the manufacturer’s instructions. The libraries were sequenced using a
HiSeq 2500 sequencing system (Illumina, San Diego, CA, USA).
Single-cell RNA sequencing data analysis. From the raw FASTQ files of scRNA-
seq data (forward/reverse strands and barcode sequence), we used Cell Ranger
analysis pipelines (v2.1.1) to obtain a gene-count matrix. We used the Seurat
version3.017,70 pipeline to analyze scRNA-seq data. For quality control, we filtered
cells with a higher percentage of mitochondrial genes or those showing outlier
behavior in nfeatures_RNA and nCount_RNA from the “FeatureScatter” plot for
each sample as recommended. We then normalized the data using the “Normal-
izeData” function with the recommended setting (log-normalization scale factor of
10,000). The normalized samples were integrated with 7431 highly variable genes
by integration functions (“FindIntegrationAnchors” and “IntegrationData”) with
default settings. For dimension reduction and visualization of the integrated data,
“ScaleData,” “RunPCA,” and “RunUMAP” functions were used with default set-
tings. Unsupervised clustering was performed by “FindNeighbors,” which conducts
shared-nearest-neighbor-based clustering with 2000 highly variable genes and
“FindClusters,” which conducts Louvain clustering (dimension of 20 and resolu-
tion of 0.65). The parameters for UMAP plotting before batch correction were the
same as those for the integrated one.
Comparative single-cell transcriptome analysis based on Pearson residual. To
investigate proportional changes between sample groups (e.g., EFGR-WT and
EGFR-MT) across cell subsets defined by clustering, we evaluated deviations in the
observed cell count for each group from the expected count for a subset using
Pearson residual:





where i and j represent indices for each group and cell subsets, respectively, and O
and E represent the observed and expected cell counts, respectively. The expected





where Ttot, Ti, Tj represent total cell count for the entire data set, total cell count for
a group i, and total cell count for a subset j, respectively. The advantage of the
Pearson residual is that the sign of the residual indicates the direction of the
difference of the observed count from the expected count (i.e., positive for aug-
mentation and negative for depletion compared to expected count). Pearson
residual (r) follows an approximately normal distribution; thus, scores larger than 2
or smaller than −2 are significant by p < 0.05. For a highly conservative statistical
test along with Bonferroni correction for multiple hypothesis test adjustment, we
used a significance threshold of p-value = 0.00056 (p-value of 0.01 was divided by
the number of subsets, 18, for Bonferroni correction). Thus, we considered only cell
subsets with r > 3.5 (augmentation) and r <−3.5 (depletion) for follow-up func-
tional interpretation. We visualized the results of the goodness of fit test using a
mosaic plot, in which subsets with deviation in observed cell counts from the
expected cell counts are indicated by blue (augmentation), red (depletion), or gray
(no significant change) colors. The goodness of fit for all subsets was also evaluated
by the chi-square statistic (p-value).
Categorizing cell subsets into major immune cell types. We used marker gene
expression to categorize cell clusters into immune cell types. The following list of
marker genes was adapted from the Reference Gene Expression Profiles (RGEP)71:
CD3D, CD3E, CD3G, and CD28 for T cells; CD4 for CD4+ T cells; CD8A and
CD8B for CD8+ T cells; FOXP3 and IL2RA for Treg cells; FCGR3A, FCGR3B,
NCAM1, KLRB1, KLRC1, KLRD1, KLRF1, and KLRK1 for NK and NKT cells;
CD14, CD68, CD163, and C8F1R for macrophages and monocytes; CD19, MS4A1,
CD79A, CD79B, and BLNK for B cells; IL3RA, CLEC4C, and NRP1 for dendritic
cells; and KIT and IL1RL1 for ILC2 cells. The expression of these marker genes was
Fig. 6 TFH–B–TRM lymphocyte cooperation and their co-localization in lung tumors. a The dot plot summarizing the cell–cell interactions among CD8-C2
(TRM-like), B, and CD4-C9 (TFH-like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle
indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed
immunofluorescence (IF) of TLS-like lesion in EGFR-WT (n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT (n = 14)
(lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT (n = 5) and
EGFR-MT (n = 4) tumors for single-cell analysis (**p≤ 0.005, two-sided test) (upper panel) and in EGFR-WT (n = 9) and EGFR-MT (n = 10) tumors from
independent patients for validation (*p≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, CXCR5, and
CD20 in tumor specimens from EGFR-WT (n = 14) (left) (scale bar 100 μm) and EGFR-MT (n = 14) (right) (scale bar 100 μm) patients. d Summarized
graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT (n = 5) and EGFR-MT (n = 4) patients. The number of CD4+, CXCL13+CD4+
T cells, CD8+ T cells, CD103+ CD8+ T cells are significantly higher in EGFR-WT than EGFR-MT (*p≤ 0.05, **p≤ 0.005, two-sided test). e Summarized
graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT (n = 9) and EGFR-MT (n = 10) tumors from independent patients for
validation. Consistently, the number of CD4+, CXCL13+CD4+ T cells, CD8+ T cells, CD103+ CD8+ T cells were significantly higher in EGFR-WT than
EGFR-MT (**p≤ 0.005, ***p≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for TFH–B–TRM lymphocyte cooperation in TLS for
antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.
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visualized as violin plots (Supplementary Fig. S2) and validated on UMAP (Sup-
plementary Figs. S3–9).
Differentially expressed gene analysis with single-cell transcriptome data.
We performed two types of DEG analysis using the “FindMarkers” function. The
“group-DEG” was evaluated by comparing the EGFR-WT group to the EGFR-MT
group for each subset. The “subset-DEG” was evaluated by comparing one subset
to all other subsets within a major cell type (i.e., NK and NKT cells, CD4+ T cells,
CD8+ T cells). DEGs were accepted if their respective q-value was smaller than
0.05 and |avgLogFC| > 0.25 (default threshold by Seurat package). We excluded
genes with high expression but a low ratio of non-zero cells.
Multiplex immunofluorescence staining. We cut 4-μm-thick tissue sections from
formalin-fixed paraffin-embedded blocks, and then performed multiplexed IF for
the nine patients analyzed by scRNA-seq, except P3 that was not available owing to
the insufficient quantities. Tissue slides were heated for at least 1 h in a dry oven at
60 °C, dewaxed using xylene, and evaluated by multiplex immunofluorescence
staining with a Leica Bond Rx™ Automated Stainer (Leica Biosystems, Wetzlar,
Germany). Briefly, the slides were heated for 30 min and dewaxed with Leica Bond
Dewax solution (#AR9222), followed by antigen retrieval with Bond Epitope
Retrieval 2 (#AR9640, Leica Biosystems) in pH 9.0 solution for 30 min. Each
primary antibody was incubated for 30 min, followed by detection using the
polymer HRP Ms+Rb secondary antibody (ARH1001EA, Akoya Biosciences,
Marlborough, MA, USA) for 10 min. To evaluate the CD103, GZMB in CD8+
T cells, primary antibodies against the following antigens were used: CD8
(MCA1817, Bio-Rad, Hercules, CA, USA, 1:300), CD103 (ab129202, Abcam,
Cambridge, UK, 1:500), and GZMB (262A-15, Cell Marque, Rocklin, CA, USA,
1:50). Visualization of each antibody was accomplished by treatment with Opal 520
TSA Plus, Opal 620 TSA Plus, and Opal 780 TSA Plus, respectively, for 10 min,
following which the slide was treated with Bond Epitope Retrieval 1 (#AR9961,
Leica Biosystems) for 20 min to remove bound antibodies. To evaluate the
CXCL13+CD4, CXCR5+CD20, CD103+CD8, we performed another set of mul-
tiplexed IF using primary antibodies against the following antigens: for CD4
(ab133616, Abcam, Cambridge, UK, 1:200), CD8 (MCA1817, Bio-Rad, Hercules,
CA, USA, 1:300), CXCL13 (PA5-47035, Invitrogen, Massachusetts, USA, 1:40),
CXCR5 (72172 S, Cell Signaling Technology, Massachusetts, USA, 1:200), CD20
(ab9475, Abcam, Cambridge, UK, 1:100), and CD103 (ab129202, Abcam, Cam-
bridge, UK, 1:500). Visualization of each antibody was accomplished by treatment
with Opal 570 TSA, Opal 520 TSA, Opal 690 TSA, Opal 620 TSA, Opal 480 TSA,
Opal 780 TSA. Nuclei were visualized with DAPI, and the section was coverslipped
using HIGHDEF® IHC fluoromount (ADI-950-260-0025, Enzo, Farmingdale, NY,
USA). To validate the results from the prior tumor samples, we conducted addi-
tional multiplex IF for tumor samples from 19 independent NSCLC patients
(EGFR-WT, n = 9; EGFR-MT, n = 10) using CD8 (MCA1817, Bio-Rad, Hercules,
CA, USA, 1:300), CD103 (ab129202, Abcam, Cambridge, UK, 1:500), CXCL13
(PA5-47035, Invitrogen, Massachusetts, USA, 1:40), CD4 (ab133616, Abcam,
Cambridge, UK, 1:200), CD20 (ab9475, Abcam, Cambridge, UK, 1:100) and CK
(NBP2-29429, NOVUS, Centennial, USA, 1:200). Visualization of each antibody
was accomplished by treatment with Opal 570 TSA, Opal 520 TSA, Opal 690 TSA,
Opal 620 TSA, Opal 480 TSA, and Opal 780 TSA.
Image acquisition and quantitative data analysis. Slides were scanned using a
Vectra Polaris Automated Quantitative Pathology Imaging System (Akoya Bios-
ciences), and images were analyzed using InForm 2.2 software and TIBCO Spot-
fire™ (Akoya Biosciences). To acquire reliable unmixed images, representative slides
of each emission spectrum and unstained tissue slide were used. Each stained
section was used to establish the spectral library of fluorophores required for
multispectral analysis as a reference for target quantitation, as the intensity of each
fluorescent target was extracted from the multispectral data by linear unmixing.
Each cell was identified by detecting nuclear spectral elements (DAPI). The
immune cell population from each panel was characterized and quantified using
the cell segmentation tool in InForm image analysis software. For co-expression
analysis, the data obtained from InForm were sent to Spotfire™ software, and the
threshold for positivity of each factor was determined using IF scoring methods. All
cells on each slide were designated as positive or negative for each antibody, and
the data were categorized and exported to a Microsoft Excel spreadsheet file for
analysis. We used the Spotfire™ program, after tissue and cell segmentation, and
compared the expression intensity, and assessed our results based on the cutoff
values. The number of positive cells was counted on each slide. Immune subsets
including GZMB+ CD103+CD8+, CD103+CD8+, CD8+, CXCL13+CD4+, and
CD4+ T cells were quantified by cell counts per mm2 in both the tumor nest and
stroma based on the whole slide. Pathologists reviewed each slide stained with
multiplex IF and H&E of nine patients and manually marked TLS-like lesion based
on the colocalization of CD20+ B cells, CD4+, CD8+ T cells. For the total area of
the TLS-like lesions in both the tumor nest and stroma of each sample, we also
evaluated the counts of CD103+CD8+, CD8+, CXCL13+CD4+, CD4+ T cells, and
CD20+ B cells.
Flow cytometry analysis. Flow cytometry was performed using CytoFLEX
(Beckman Coulter, Brea, CA, USA). Data were analyzed using FlowJo software
(Tree Star, Ashland, OR, USA). For immunolabeling TILs, fluorophore-conjugated
monoclonal antibodies against the following proteins were used: CD8 (RPA-T8,
Cat# 301048, Biolegend, San Diego, CA, USA, 1:50), CD3 (SK7, Cat# 344808,
Biolegend, San Diego, CA, USA, 1:100), PD-1 (EH12.2H7, Cat# 329933, Biolegend,
San Diego, CA, USA, 1:20), CD103 (Ber-ACT8, Cat# 350230, Biolegend, San
Diego, CA, USA, 1:20), CD39 (A1, Cat# 328210, Biolegend, San Diego, CA, USA,
1:20), GZMB (QA16A02, Cat# 372214, Biolegend, San Diego, CA, USA, 1:50), and
CD4 (RPA-T4, Cat# 560837, BD Biosciences, San Diego, CA, USA, 1:50). The
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit was from Invitrogen (L34973,
Waltham, Massachusetts, USA, 1:100). The sequential gating strategies used for
analysis for data obtained from flow cytometry are described in Supplementary Fig.
S15.
For t-distributed stochastic neighbor embedding (tSNE) visualization of flow
cytometry data, we used three samples for each group (EGFR-WT and EGFR-MT).
Each sample was down-sampled to 7000 randomly selected CD3+ live and singlet-
gated cells, yielding 42,000 cells. A tSNE plot for the merged 42,000 cells was
constructed using FlowJo (v10.6.2) with default settings (3000 iterations and
perplexity = 100).
RNA velocity-based estimation of cellular transition probability. We per-
formed RNA velocity analysis by velocyto52 using the default pipeline. We pro-
cessed single-cell transcriptome data for EGFR-WT and EGFR-MT tumors
separately. We used the pre-built UMAP coordinate of CD8+ T cells from the
Seurat package as the embedding coordinates for plotting. The transition prob-
ability was obtained from the “transition_prob.T” variable. RNA velocity predicts
the future mRNA abundance of each gene from the ratio of spliced and unspliced
mRNA levels based on a steady-state model. For ScVelo53 (ver 0.2.3) analysis which
enables estimation of RNA velocity without steady-state assumption, we used the
default pipeline. Loom files for splicing and un-splicing count information for each
cell were obtained from RNA velocity analysis. The transition probability was
obtained from the “scv.utials.get_transition_matrix()” class. The future state of
each cell is predicted based on all genes. For a given subset of cells, the probability
of transition to another subset can be calculated for each cell. The mean values of
transition probability for each subset of cells were obtained by averaging the
corresponding cell transition to other cell subsets.
MetaCell-based analysis of gene expression correlations. The correlation
coefficient calculated from single-cell gene expression data was markedly low,
mainly because of the zero-inflation property of scRNA-seq data. The sparsity of
single-cell expression profiles can be compensated by imputation approaches, but
they generate many false gene-gene correlations72. For more sensitive and robust
detection of co-expression between two genes, we employed MetaCell57, which
pools k nearest neighbor cells. We collected the raw count matrix from the Seurat
object of single-cell data for EGFR-WT and EGFR-MT groups, separately. Each
data set was processed using default parameter settings in the MetaCell pipeline
without a cell filtering step: T_vm = 0.08 for mcell_gset_filter_varmean; T_tot =
100 and T_top3 = 2 for mcell_gset_filter_cov; K = 100 and dsamp = T for
mcell_add_cgraph_from_mat_bknn; min_mc_size = 20, p_resamp = 0.75, and
n_resamp = 500 for mcell_coclust_from_graph_resamp; K = 30, min_mc_size =
30, and alpha = 2 for mcell_mc_from_coclust_balanced; and T_lfc = 3 for
mcell_mc_split_filt. The pooled cell “metacell” was generated with a corrected
expression matrix calculated by the regularized geometric mean of each “metacell.”
We calculated Spearman’s rank correlation coefficient between two genes based on
the corrected expression matrix.
Determining the abundance of TRM-like cells in tumor samples using
expression signature. Expression deconvolution technology was used to estimate
the proportion of the TRM-like cells from bulk RNA-seq profiles for tumor samples.
To construct a gene expression profile of TRM-like cells, we employed
CIBERSORTx58, a recently developed tool for expression deconvolution that can
utilize single-cell transcriptome data. We first generated a signature matrix of the
7431 highly variable genes based on the scRNA-seq data. We then deconvoluted
bulk RNA-seq data using default parameter settings for each tumor sample
obtained from LUAD and lung squamous cell carcinoma (LUSC) of TCGA cohort
data set73 to estimate the proportion of TRM-like cells. We also estimated the
proportion of TRM-like cells of tumor samples from two other public cohorts of
patients with lung cancer treated with anti-PD-1 immunotherapy (GSE126045 and
GSE135222)60,61.
Analysis of receptor–ligand-mediated cell–cell interactions. We used
CellPhoneDB63 to analyze the receptor–ligand-mediated cell–cell interactions. We
used the raw count matrix with the 7431 highly variable genes based on the
scRNA-seq data for cells of C0–14 clusters as input data. We ran the EGFR-WT
and EGFR-MT data separately with the default pipeline and parameters.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The single-cell RNA sequencing data generated in this study have been deposited in the
Gene Expression Omnibus database (GSE144945). TCGA cohort data set were obtained
from [https://gdac.broadinstitute.org]59. Bulk RNA-seq data for two public cohorts of
patients with lung cancer treated with anti-PD-1 immunotherapy were obtained from
GSE12604560 and GSE13522261. The remaining data are available within the Article,
Supplementary Information, or Source Data file. Source data are provided with
this paper.
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